ReviewInternational journal of molecular sciences2023
Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06934447 (Study of BCMA/CD70 Targeted Chimeric Antigen Receptor T), which is not on this map. Cited by 71 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of BCMA/CD70 Targeted Chimeric Antigen Receptor T (CAR- T) Therapy for Refractory Childhood-oneset Systemic Lupus Erythematosus
Who cites it
71 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Unravelling the connection between interferons and systemic lupus erythematosus: a systematic review and meta-analysis.BMC medicine · 2025Pooled it
- A Systematic Review and Meta-Analysis of the Effects of Vitamin D on Systemic Lupus Erythematosus.Nutrients · 2025Pooled it
- Efficacy and Safety of Biologics for Systemic Lupus Erythematosus (SLE): A Systematic Review and Network Meta-Analysis.Clinical reviews in allergy & immunology · 2025Pooled it
- Risk factors for adverse maternal and fetal outcomes in SLE patients: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- The vascular endothelial growth factor as a candidate biomarker of systemic lupus erythematosus: a GRADE-assessed systematic review and meta-analysis.Clinical and experimental medicine · 2024Pooled it
- Imbalance of Th17 cells, Treg cells and associated cytokines in patients with systemic lupus erythematosus: a meta-analysis.Frontiers in immunology · 2024Pooled it
- Serum lipid profile in systemic lupus erythematosus.Frontiers in immunology · 2024Pooled it
- Trial
- Jianpi Zishen Decoction ameliorates renal damage induced by systemic lupus erythematosus through inhibition of the TLR4/MAPK pathway.Pharmaceutical biology · 2026Article
- Review
- Lupus nephritis and kidney transplantation: A narrative review of patient and graft outcomes.World journal of nephrology · 2026Review
- Effect Of treatment on serum C3, C4, IL-10, IL1-β, IL-6, TNF-α in patients with systemic lupus erythematosus.Journal of medical biochemistry · 2026Article
- Integrative transcriptomic and systems biology analysis of public SLE datasets identifies immune regulatory pathways.Journal of computer-aided molecular design · 2026Article
- Potential Roles of Prostaglandins PGD2, PGJ2, and PGE2 in the Pathogenesis of Systemic Lupus Erythematosus.International journal of molecular sciences · 2026Review
- Application of the SLERPI scoring system as a classification tool in systemic lupus erythematosus and its performance in early disease recognition.Rheumatology international · 2026Article
- The DHCQ/HCQ metabolic ratio and CYP2C8 Genotype are associated with lipid profile improvement in systemic lupus erythematosus patients treated with hydroxychloroquine.Arthritis research & therapy · 2026Article
- Challenges of modeling pristane-induced lupus in non-human primates.Animal models and experimental medicine · 2026Article
- Association of metabolic and inflammation vulnerabilities with systemic lupus erythematosus: a prospective UK Biobank study.Frontiers in immunology · 2026Article
- Immunometabolic dysregulation in autoimmune rheumatic diseases: the central role of glycolytic reprogramming in pathogenesis and traditional Chinese medicine therapy.Frontiers in immunology · 2026Review
- Therapeutic potential of TAM receptors in autoimmune diseases: insights from original studies.Oxford open immunology · 2026Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant disease, characterized by multiple organ damage, that in its most severe forms can be life-threatening. The pathogenesis of SLE is complex and involves cells of both innate and adaptive immunity. The distinguishing feature of SLE is the production of autoantibodies, with the formation of immune complexes that precipitate at the vascular level, causing organ damage. Although progress in understanding the pathogenesis of SLE has been slower than in other rheumatic diseases, new knowledge has recently led to the development of effective targeted therapies, that hold out hope for personalized therapy. However, the new drugs available to date are still an adjunct to conventional therapy, which is known to be toxic in the short and long term. The purpose of this review is to summarize recent advances in understanding the pathogenesis of the disease and discuss the results obtained from the use of new targeted drugs, with a look at future therapies that may be used in the absence of the current standard of care or may even cure this serious systemic autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.